David Dienhart, MD
Pulmonary Disease · Murray, UTNPI 1184601940
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 642 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations.
Across 642 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Mylan Specialty L.p.$892
- Boehringer Ingelheim$721
- Insmed, Inc.$598
- Harmony Biosciences LLC$505
- plus $5K from 41 others
What the payments were for
- Food & beverage$10,36396%
- Education$3784%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$10,741 in reported general payments places this provider in the 85th percentile of 101 pulmonary disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 11 | $145,586 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 122 | $120,696 |
| Spiriva RespimatTiotropium Bromide | 83 | $78,309 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 49 | $53,603 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 34 | $32,563 |
| SymbicortBudesonide/Formoterol Fumarate | 60 | $22,952 |
| Incruse ElliptaUmeclidinium Bromide | 29 | $15,073 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 69 | $14,083 |
| Bosentan | 11 | $13,690 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $13,327 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $10,568 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $8,758 |
| Pirfenidone | 15 | $8,411 |
| BreynaBudesonide/Formoterol Fumarate | 27 | $7,582 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 135 | $4,704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $721 | $256,457128 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $1,297 | $163,630200 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,756 | $76,555109 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $35 | $13,69011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 101 pulmonary disease providers in Utah.
Other pulmonary disease in Murray
- Timothy LeclairMurray$74K
- Sunny PanditaMurray$25K
- Meghan CirulisMurray$18K
- David GuidryMurray$11K
- Lynette BrownMurray$10K
- Gregory GrandioMurray$6K
- Katie JeansMurray$3K
- Mark DodsonMurray$2K
- Samuel BrownMurray$1K
- Jeffrey GrahamMurray$408
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.